CR20150149A - Proteínas de fusión para el tratamiento de un síndrome metabólico - Google Patents
Proteínas de fusión para el tratamiento de un síndrome metabólicoInfo
- Publication number
- CR20150149A CR20150149A CR20150149A CR20150149A CR20150149A CR 20150149 A CR20150149 A CR 20150149A CR 20150149 A CR20150149 A CR 20150149A CR 20150149 A CR20150149 A CR 20150149A CR 20150149 A CR20150149 A CR 20150149A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- fusion proteins
- metabolic syndrome
- fusion protein
- adiposity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
Abstract
La invención se refiere a una proteína de fusión que comprende al menos un compuesto de FGF-21 (factor 21 de crecimiento de fibroblastos) y al menos un agonista de GLP-1R (receptor del péptido 1 similar a glucagón) así como a composiciones farmacéuticas, usos médicos y métodos de tratamiento que implican la proteína de fusión, particularmente en el campo de diabetes, dislipidemia, obesidad y/o adiposidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306072 | 2012-09-07 | ||
PCT/EP2013/068239 WO2014037373A1 (en) | 2012-09-07 | 2013-09-04 | Fusion proteins for treating a metabolic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150149A true CR20150149A (es) | 2015-05-29 |
Family
ID=46888349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150149A CR20150149A (es) | 2012-09-07 | 2015-03-19 | Proteínas de fusión para el tratamiento de un síndrome metabólico |
Country Status (25)
Country | Link |
---|---|
US (3) | US20140073563A1 (es) |
EP (1) | EP2892919A1 (es) |
JP (1) | JP2015533483A (es) |
KR (1) | KR20150043505A (es) |
CN (1) | CN104736558A (es) |
AR (1) | AR092456A1 (es) |
AU (1) | AU2013311777B2 (es) |
BR (1) | BR112015004734A2 (es) |
CA (1) | CA2880929A1 (es) |
CL (1) | CL2015000379A1 (es) |
CR (1) | CR20150149A (es) |
DO (1) | DOP2015000020A (es) |
EA (1) | EA201590525A1 (es) |
GT (1) | GT201500049A (es) |
HK (1) | HK1207097A1 (es) |
IL (1) | IL237032A0 (es) |
MA (1) | MA37963A1 (es) |
MX (1) | MX2015002985A (es) |
PE (1) | PE20150648A1 (es) |
PH (1) | PH12015500194A1 (es) |
SG (1) | SG11201500682WA (es) |
TN (1) | TN2015000053A1 (es) |
TW (1) | TW201414750A (es) |
UY (1) | UY35018A (es) |
WO (1) | WO2014037373A1 (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2682147C (en) | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
JP6403685B2 (ja) | 2012-12-27 | 2018-10-17 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法 |
ES2753264T3 (es) | 2013-10-28 | 2020-04-07 | Ngm Biopharmaceuticals Inc | Modelos de cáncer y métodos asociados |
MY191944A (en) | 2014-01-24 | 2022-07-20 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
EP3125921B1 (en) | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
IL294063A (en) * | 2014-07-29 | 2022-08-01 | Shenzhen Hightide Biopharmaceutical Ltd | Salts of berberic acid, salts of ursodeoxycholic acid and their combinations, methods for their preparation and their uses |
KR102569907B1 (ko) | 2014-10-23 | 2023-08-24 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법 |
LT3412302T (lt) | 2014-10-24 | 2021-07-26 | Bristol-Myers Squibb Company | Modifikuoti fgf-21 polipeptidai ir jų panaudojimai |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
KR102427527B1 (ko) * | 2014-12-23 | 2022-08-01 | 노보 노르디스크 에이/에스 | Fgf21 유도체 및 그것의 용도 |
CN105801705B (zh) * | 2014-12-31 | 2019-05-24 | 天境生物科技(上海)有限公司 | 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途 |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
WO2017024182A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
KR20170049320A (ko) * | 2015-10-28 | 2017-05-10 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
CA3082794A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methods for treatment of bile acid-related disorders |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
DK3402811T3 (da) | 2016-01-13 | 2022-06-13 | Novo Nordisk As | Egf(a)-analoger med fedtsyresubstituenter |
WO2017186250A1 (en) * | 2016-04-29 | 2017-11-02 | Defensin Therapeutics Aps | Treatment of liver, biliary tract and pancreatic disorders |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN107759696A (zh) * | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
BR112019012693A2 (pt) * | 2016-12-22 | 2019-11-19 | Sanofi Sa | combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada |
WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
US20220127322A1 (en) * | 2017-03-14 | 2022-04-28 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
EP3612637A4 (en) | 2017-04-21 | 2021-01-27 | Yuhan Corporation | DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES |
WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS |
BR112020001286A2 (pt) | 2017-07-19 | 2020-07-28 | Novo Nordisk A/S | composto, e, método de tratamento da diabetes, sobrepeso e/ou doenças cardiovasculares |
KR20200054303A (ko) | 2017-09-22 | 2020-05-19 | 리제너론 파아마슈티컬스, 인크. | 글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도 |
ES2923152T3 (es) * | 2017-11-06 | 2022-09-23 | Thena Biotech S R L | Proteínas de fusión basadas en ferritina humana y péptidos escindibles por proteasas y su uso como vehículos quimioterapéuticos |
CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
WO2019119673A1 (zh) * | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | 一种双基因修饰的干细胞及其用途 |
CN113603794B (zh) * | 2018-01-11 | 2024-01-16 | 安源医药科技(上海)有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
AU2019218147B2 (en) * | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
JP2021528422A (ja) * | 2018-06-21 | 2021-10-21 | サノフイSanofi | 最適化された活性比を有するfgf21化合物/glp−1rアゴニストの組合せ |
EP3829622A4 (en) * | 2018-08-02 | 2022-05-11 | Duke University | DUAL AGONIST FUSION PROTEINS |
CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
CN114853908A (zh) * | 2019-05-16 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
CN115322794A (zh) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
CN113735977A (zh) * | 2020-05-28 | 2021-12-03 | 江苏康缘瑞翱生物医药科技有限公司 | rhFGF21融合蛋白、编码其的多核苷酸、包含其组合物及其用途 |
US20220010021A1 (en) | 2020-07-02 | 2022-01-13 | Sanofi | FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides |
TW202216747A (zh) * | 2020-07-10 | 2022-05-01 | 南韓商Gi醫諾微新股份有限公司 | 包含類升糖素胜肽—1及介白素—1受體拮抗物的融合蛋白及其用途 |
WO2022117044A1 (en) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof |
AR125086A1 (es) * | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Composiciones que contienen análogos de incretina y usos de estas |
CN113150172B (zh) * | 2021-04-28 | 2023-09-22 | 中国药科大学 | Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用 |
WO2022256568A1 (en) * | 2021-06-02 | 2022-12-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for localization of growth factors |
WO2023284822A1 (en) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
CN113583142A (zh) * | 2021-08-20 | 2021-11-02 | 赣江中药创新中心 | 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法 |
WO2023049631A2 (en) * | 2021-09-09 | 2023-03-30 | Northwestern University | Cell-free methods and compositions comprising tagless therapeutic hormones |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
CN117801125A (zh) * | 2024-02-29 | 2024-04-02 | 天津凯莱英生物科技有限公司 | 艾塞那肽前体的融合蛋白及其应用 |
CN117801124A (zh) * | 2024-02-29 | 2024-04-02 | 天津凯莱英生物科技有限公司 | 利西那肽前体的融合蛋白及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03219892A (ja) * | 1990-01-24 | 1991-09-27 | Kyowa Hakko Kogyo Co Ltd | タンパク質の製造法 |
GB9725556D0 (en) * | 1997-12-03 | 1998-02-04 | Ciba Geigy Ag | Organic compounds |
CZ20012406A3 (cs) * | 1999-01-07 | 2002-03-13 | Lexigen Pharmaceuticals, Corp. | Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
US7901688B2 (en) * | 2004-08-03 | 2011-03-08 | Transtech Pharma, Inc. | Rage fusion proteins |
CN105950667A (zh) * | 2005-07-05 | 2016-09-21 | 加利福尼亚大学董事会 | 编码类异戊烯修饰酶的多核苷酸和其使用方法 |
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
US7825093B2 (en) * | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
JP2010535781A (ja) * | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
WO2009023270A2 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
CN116925238A (zh) * | 2009-02-03 | 2023-10-24 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
AU2010306774A1 (en) * | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
WO2011084808A2 (en) * | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
EP2825557B1 (en) * | 2012-03-16 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Soluble engineered monomeric fc |
-
2013
- 2013-09-04 EP EP13758851.3A patent/EP2892919A1/en not_active Withdrawn
- 2013-09-04 BR BR112015004734A patent/BR112015004734A2/pt not_active IP Right Cessation
- 2013-09-04 CN CN201380046749.3A patent/CN104736558A/zh active Pending
- 2013-09-04 JP JP2015530371A patent/JP2015533483A/ja active Pending
- 2013-09-04 AU AU2013311777A patent/AU2013311777B2/en not_active Ceased
- 2013-09-04 WO PCT/EP2013/068239 patent/WO2014037373A1/en active Application Filing
- 2013-09-04 SG SG11201500682WA patent/SG11201500682WA/en unknown
- 2013-09-04 CA CA2880929A patent/CA2880929A1/en not_active Abandoned
- 2013-09-04 EA EA201590525A patent/EA201590525A1/ru unknown
- 2013-09-04 PE PE2015000288A patent/PE20150648A1/es not_active Application Discontinuation
- 2013-09-04 MA MA37963A patent/MA37963A1/fr unknown
- 2013-09-04 KR KR1020157007317A patent/KR20150043505A/ko not_active Application Discontinuation
- 2013-09-04 MX MX2015002985A patent/MX2015002985A/es unknown
- 2013-09-05 AR ARP130103163A patent/AR092456A1/es unknown
- 2013-09-06 TW TW102132110A patent/TW201414750A/zh unknown
- 2013-09-06 UY UY0001035018A patent/UY35018A/es not_active Application Discontinuation
- 2013-09-06 US US14/019,735 patent/US20140073563A1/en not_active Abandoned
-
2015
- 2015-01-29 PH PH12015500194A patent/PH12015500194A1/en unknown
- 2015-02-01 IL IL237032A patent/IL237032A0/en unknown
- 2015-02-05 DO DO2015000020A patent/DOP2015000020A/es unknown
- 2015-02-17 CL CL2015000379A patent/CL2015000379A1/es unknown
- 2015-02-18 TN TNP2015000053A patent/TN2015000053A1/fr unknown
- 2015-02-27 GT GT201500049A patent/GT201500049A/es unknown
- 2015-03-19 CR CR20150149A patent/CR20150149A/es unknown
- 2015-08-13 HK HK15107811.5A patent/HK1207097A1/xx unknown
- 2015-12-10 US US14/965,841 patent/US20160194371A1/en not_active Abandoned
-
2018
- 2018-07-27 US US16/047,695 patent/US20190085043A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104736558A (zh) | 2015-06-24 |
EA201590525A1 (ru) | 2015-07-30 |
WO2014037373A1 (en) | 2014-03-13 |
IL237032A0 (en) | 2015-03-31 |
BR112015004734A2 (pt) | 2017-11-21 |
TW201414750A (zh) | 2014-04-16 |
MA37963A1 (fr) | 2018-06-29 |
PH12015500194A1 (en) | 2015-04-20 |
KR20150043505A (ko) | 2015-04-22 |
AU2013311777B2 (en) | 2018-02-01 |
UY35018A (es) | 2014-03-31 |
SG11201500682WA (en) | 2015-02-27 |
MX2015002985A (es) | 2015-06-22 |
AU2013311777A1 (en) | 2015-03-19 |
CA2880929A1 (en) | 2014-03-13 |
CL2015000379A1 (es) | 2015-06-05 |
AR092456A1 (es) | 2015-04-22 |
US20190085043A1 (en) | 2019-03-21 |
HK1207097A1 (en) | 2016-01-22 |
EP2892919A1 (en) | 2015-07-15 |
TN2015000053A1 (en) | 2016-06-29 |
JP2015533483A (ja) | 2015-11-26 |
US20160194371A1 (en) | 2016-07-07 |
US20140073563A1 (en) | 2014-03-13 |
DOP2015000020A (es) | 2015-04-15 |
GT201500049A (es) | 2016-02-15 |
PE20150648A1 (es) | 2015-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150149A (es) | Proteínas de fusión para el tratamiento de un síndrome metabólico | |
UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
CO7151525A2 (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
AR092076A1 (es) | Proteinas homodimericas | |
CL2012002031A1 (es) | Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente. | |
CR20140142A (es) | Variantes delfactor 21 del crecimiento de fibroblastos | |
CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
MX2014015258A (es) | Variantes del factor 21 de crecimiento de fibroblasto. | |
UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
EA201591123A1 (ru) | Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств | |
UA114792C2 (uk) | Коагоніст глюкагонового рецептора/glp-1-рецептора |